Pediatric lupus nephritis: More options, more chances?

Lupus

Volumn 22, Issue 6, 2013, Pages 545-553

  Vachvanichsanong, P ^a   McNeil, E ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Cyclophosphamide; lupus nephritis; mycophenolate mofetil; systemic lupus erythematosus (SLE); therapy

Indexed keywords

ABATACEPT; ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATACICEPT; AZATHIOPRINE; BELATACEPT; BELIMUMAB; CLADRIBINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; EPRATUZUMAB; FLUDARABINE; FORIGERIMOD; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; TOCILIZUMAB; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; CHILD; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFECTION; KIDNEY FUNCTION; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); NAUSEA; NAUSEA AND VOMITING; OVARY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RENAL REPLACEMENT THERAPY; REPRODUCTIVE TOXICITY; REVIEW; SIDE EFFECT; STEROID THERAPY; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRAL RESPIRATORY TRACT INFECTION;

CYCLOPHOSPHAMIDE; LUPUS NEPHRITIS; MYCOPHENOLATE MOFETIL; SYSTEMIC LUPUS ERYTHEMATOSUS (SLE); THERAPY;

ADULT; AGE OF ONSET; CHILD; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84878333191     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313485490     Document Type: Review

References (91)

1. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010 ; 39: 257-268
2. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: A longitudinal study. J Pediatr. 2008 ; 152: 550-556
3. von Scheven E, Bakkaloglu A. What's new in paediatric SLE?. Best Pract Res Clin Rheumatol. 2009 ; 23: 699-708
4. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: A comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995 ; 34: 866-872
5. Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am. 2002 ; 28: 561-577, vi-vii
6. Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol. 1994 ; 8: 230-249
7. Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE - towards a comprehensive management plan. Nat Rev Rheumatol. 2011 ; 7: 225-233
8. Hiraki LT, Lu B, Alexander SR, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum. 2011 ; 63: 1988-1997
9. Vachvanichsanong P, Dissaneewate P, Lim A, McNeil E. Childhood acute renal failure: 22-year experience in a university hospital in southern Thailand. Pediatrics. 2006 ; 118: e786 - e791
10. Vachvanichsanong P, Dissaneewate P, McNeil E. Childhood chronic kidney disease in a developing country. Pediatr Nephrol. 2008 ; 23: 1143-1147
11. Vachvanichsanong P, Dissaneewate P, McNeil E. Twenty-two years' experience with childhood-onset SLE in a developing country: Are outcomes similar to developed countries?. Arch Dis Child. 2011 ; 96: 44-49
12. Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erythematosus (SLE): Lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 2008 ; 17: 437-442
13. Daleboudt GM, Bajema IM, Goemaere NN, van Laar JM, Bruijn JA, Berger SP. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant. 2009 ; 24: 3712-3717
14. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 ; 15: 241-250
15. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999 ; 10: 413-424
16. Emre S, Bilge I, Sirin A, et al. Lupus nephritis in children: Prognostic significance of clinicopathological findings. Nephron. 2001 ; 87: 118-126
17. Bogdanović R, Nikolić V, Pasić S, et al. Lupus nephritis in childhood: A review of 53 patients followed at a single center. Pediatr Nephrol. 2004 ; 19: 36-44
18. Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol. 2002 ; 29: 2635-2642
19. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005 ; 16: 1076-1084
20. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004 ; 350: 971-980
21. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med. 1987 ; 83: 877-885
22. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007 ; 22: 2531-2539
23. Vachvanichsanong P, Dissaneewate P, McNeil E. Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood-onset lupus nephritis: A 23-year experience in a single centre. Nephrol Dial Transplant. 2009 ; 24: 2729-2734
24. Wong SN, Chan WK, Hui J, et al. Membranous lupus nephritis in Chinese children - a case series and review of the literature. Pediatr Nephrol. 2009 ; 24: 1989-1996
25. Cramer CH, Mills M, Valentini RP, Smoyer WE, Haftel H, Brophy PD. Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis. Nephrol Dial Transplant. 2007 ; 22: 3495-3500
26. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 ; 71: 1771-1782
27. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 ; 78: 167-175
28. Al Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus. 2009 ; 18: 465-473
29. Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006 ; 119: 355.e25-355e.33
30. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: Emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995 ; 122: 940-950
31. Walsh M, Jayne D, Moist L, Tonelli M, Pannu N, Manns B. Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. Lupus. 2010 ; 19: 628-633
32. Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol. 2005 ; 17: 568-573
33. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004 ; 43: 197-208
34. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006 ; 70: 732-742
35. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010 ; 69: 61-64
36. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: A systematic review and meta-analysis. Lupus. 2010 ; 19: 703-710
37. Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 ; 340: 741-745
38. Ciruelo E, de la Cruz J, López I, Gómez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. 1996 ; 39: 2028-2034
39. El Hachmi M, Jadoul M, Lefèbvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome. Lupus. 2003 ; 12: 692-696
40. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Longâ€term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002 ; 46: 995-1002
41. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000 ; 57: 258-264
42. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996 ; 50: 2047-2053
43. Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002 ; 61: 1502-1509
44. Benseler SM, Bargman JM, Feldman BM, et al. Acute renal failure in paediatric systemic lupus erythematosus: Treatment and outcome. Rheumatology (Oxford). 2009 ; 48: 176-182
45. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr. 2000 ; 136: 243-247
46. Vachvanichsanong P, Dissaneewate P, McNeil E. Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis. Int Urol Nephrol. 2012 Dec 7. [Epub ahead of print] ;:
47. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004 ; 50: 2559-2568
48. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 ; 343: 1156-1162
49. Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf. 2008 ; 7: 219-222
50. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228
51. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005 ; 10: 504-510
52. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
53. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006 ; 8: R182 - R182
54. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007 ; 2: 968-975
55. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007 ; 22: 1933-1942
56. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001 ; 357: 1027-1032
57. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: A systematic review and metaanalysis. J Rheumatol. 2011 ; 38: 69-78
58. Tullus K. New developments in the treatment of systemic lupus erythematosus. Pediatr Nephrol. 2012 ; 27: 727-732
59. Paredes A. Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis?. Pediatr Nephrol. 2007 ; 22: 1077-1082
60. Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child. 2010 ; 95: 1059-1061
61. Feutren G. Cyclosporin A: Recent developments in the mechanism of action and clinical application. Curr Opin Immunol. 1989 ; 2: 239-245
62. Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical study. Br J Rheumatol. 1996 ; 35: 669-675
63. Caccavo D, Lagana B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum. 1997 ; 40: 27-35
64. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: Pointing to the future. Curr Opin Rheumatol. 2005 ; 17: 550-557
65. Nwobi O, Abitbol CL, Chandar J, et al. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008 ; 23: 413-419
66. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005 ; 52: 3168-3174
67. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis. 1997 ; 56: 690-692
68. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 ; 19: 2001-2010
69. Haubitz M. New and emerging treatment approaches to lupus. Biologics. 2010 ; 4: 263-271
70. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010 ; 21: 2028-2035
71. Vasudevan A, Krishnamurthy AN. Changing worldwide epidemiology of systemic lupus erythematosus. Rheum Dis Clin North Am. 2010 ; 36: 1-13, vii
72. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009 ; 18: 257-263
73. Singh A, Kamen DL. Potential benefits of vitamin D for patients with systemic lupus erythematosus. Dermatoendocrinol. 2012 ; 4: 146-151
74. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus. 2008 ; 17: 426-430
75. Bunnapradist S, Chung P, Peng A, et al. Outcomes of renal transplantation for recipients with lupus nephritis: Analysis of the Organ Procurement and Transplantation Network database. Transplantation. 2006 ; 82: 612-618
76. Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: A recommended treatment approach. Drugs. 2006 ; 66: 1191-1207
77. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: Long-term follow-up. Nephrol Dial Transplant. 2006 ; 21: 1541-1548
78. Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr. 2010 ; 99: 967-974
79. Ponticelli C. Treatment of lupus nephritis - the advantages of a flexible approach. Nephrol Dial Transplant. 1997 ; 12: 2057-2059
80. Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 ; 64: 375-383
81. Wong SN, Tse KC, Lee TL, et al. Lupus nephritis in Chinese children - a territory-wide cohort study in Hong Kong. Pediatr Nephrol. 2006 ; 21: 1104-1112
82. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of the renal outcome of pediatric lupus nephritis. Clin Rheumatol. 2004 ; 23: 318-323
83. Miettunen PM, Ortiz-Alvarez O, Petty RE, et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J Rheumatol. 2004 ; 31: 1650-1654
84. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect. 2003 ; 36: 203-208
85. Yang LY, Chen WP, Lin CY. Lupus nephritis in children - a review of 167 patients. Pediatrics. 1994 ; 94: 335-340
86. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology (Oxford). 2010 ; 49: 128-140
87. Petri M. Lupus in Baltimore: Evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. Lupus. 2005 ; 14: 970-973
88. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 ; 135: 248-257
89. Huang JL, Lin CJ, Hung IJ, Luo SF. The morbidity and mortality associated with childhood onset systemic lupus erythematosus. Changgeng Yi Xue Za Zhi. 1994 ; 17: 113-120
90. Chen MJ, Tseng HM, Huang YL, et al. Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology (Oxford). 2008 ; 47: 1352-1357
91. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999 ; 92: 211-218